Mainz Biomed (MYNZ) Competitors $0.24 0.00 (0.00%) (As of 11/5/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends MYNZ vs. BIOR, INDP, INAB, WENA, CLDI, CERO, AYTU, KPRX, ADXN, and EDSAShould you be buying Mainz Biomed stock or one of its competitors? The main competitors of Mainz Biomed include Biora Therapeutics (BIOR), Indaptus Therapeutics (INDP), IN8bio (INAB), ANEW Medical (WENA), Calidi Biotherapeutics (CLDI), CERo Therapeutics (CERO), Aytu BioPharma (AYTU), Kiora Pharmaceuticals (KPRX), Addex Therapeutics (ADXN), and Edesa Biotech (EDSA). These companies are all part of the "pharmaceutical products" industry. Mainz Biomed vs. Biora Therapeutics Indaptus Therapeutics IN8bio ANEW Medical Calidi Biotherapeutics CERo Therapeutics Aytu BioPharma Kiora Pharmaceuticals Addex Therapeutics Edesa Biotech Biora Therapeutics (NASDAQ:BIOR) and Mainz Biomed (NASDAQ:MYNZ) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, community ranking, risk, earnings, valuation and institutional ownership. Is BIOR or MYNZ more profitable? Company Net Margins Return on Equity Return on Assets Biora TherapeuticsN/A N/A -228.89% Mainz Biomed N/A N/A N/A Do insiders & institutionals have more ownership in BIOR or MYNZ? 43.7% of Biora Therapeutics shares are held by institutional investors. 51.1% of Biora Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, BIOR or MYNZ? Biora Therapeutics has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.07, indicating that its share price is 93% less volatile than the S&P 500. Which has better valuation & earnings, BIOR or MYNZ? Mainz Biomed has higher revenue and earnings than Biora Therapeutics. Mainz Biomed is trading at a lower price-to-earnings ratio than Biora Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiora TherapeuticsN/AN/A-$124.11M-$56.90-0.05Mainz Biomed$900KN/A-$26.30M-$1.64-0.14 Do analysts recommend BIOR or MYNZ? Biora Therapeutics presently has a consensus target price of $150.00, indicating a potential upside of 5,334.78%. Mainz Biomed has a consensus target price of $3.00, indicating a potential upside of 1,167.43%. Given Biora Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Biora Therapeutics is more favorable than Mainz Biomed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biora Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Mainz Biomed 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the MarketBeat Community prefer BIOR or MYNZ? Mainz Biomed received 6 more outperform votes than Biora Therapeutics when rated by MarketBeat users. However, 77.78% of users gave Biora Therapeutics an outperform vote while only 76.47% of users gave Mainz Biomed an outperform vote. CompanyUnderperformOutperformBiora TherapeuticsOutperform Votes777.78% Underperform Votes222.22% Mainz BiomedOutperform Votes1376.47% Underperform Votes423.53% Does the media refer more to BIOR or MYNZ? In the previous week, Biora Therapeutics had 1 more articles in the media than Mainz Biomed. MarketBeat recorded 1 mentions for Biora Therapeutics and 0 mentions for Mainz Biomed. Biora Therapeutics' average media sentiment score of 0.00 equaled Mainz Biomed'saverage media sentiment score. Company Overall Sentiment Biora Therapeutics Neutral Mainz Biomed Neutral SummaryBiora Therapeutics beats Mainz Biomed on 8 of the 13 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Mainz Biomed News Delivered to You Automatically Sign up to receive the latest news and ratings for MYNZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYNZ vs. The Competition Export to ExcelMetricMainz BiomedPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$7.01B$5.26B$8.58BDividend YieldN/A7.98%5.12%4.03%P/E Ratio-0.149.69119.1116.00Price / SalesN/A406.041,654.4698.09Price / CashN/A22.4934.6231.48Price / Book0.885.764.804.67Net Income-$26.30M$153.41M$117.38M$223.25M7 Day Performance-12.33%-1.28%-0.16%0.41%1 Month Performance-2.15%15.22%6.18%4.69%1 Year Performance-90.38%38.12%34.70%27.26% Mainz Biomed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYNZMainz Biomed2.1443 of 5 stars$0.24flat$3.00+1,167.4%-90.2%$0.00$900,000.00-0.1430BIORBiora Therapeutics2.8046 of 5 stars$3.48-1.4%$150.00+4,210.3%-84.4%$12.80M$860,000.00-0.06120Upcoming EarningsGap DownINDPIndaptus Therapeutics3.7265 of 5 stars$1.24flat$12.00+867.7%-53.2%$12.64MN/A-0.676Gap DownINABIN8bio3.4244 of 5 stars$0.27flat$10.00+3,602.3%-70.7%$12.64MN/A-0.3320News CoverageWENAANEW MedicalN/A$0.73-0.5%N/AN/A$12.51MN/A0.00N/AGap UpCLDICalidi Biotherapeutics2.2878 of 5 stars$1.11+2.8%$16.67+1,401.5%N/A$12.33M$50,000.000.0041Gap UpHigh Trading VolumeCEROCERo TherapeuticsN/A$0.08flatN/AN/A$12.25MN/A0.008Gap DownAYTUAytu BioPharma0.7718 of 5 stars$1.99-0.5%N/A-34.1%$11.88M$81.00M-0.70160Upcoming EarningsGap UpKPRXKiora Pharmaceuticals3.781 of 5 stars$3.70-3.9%$10.00+170.3%-34.2%$11.44M$16M0.0010Positive NewsADXNAddex Therapeutics1.4885 of 5 stars$10.72+3.0%$30.00+179.9%+81.1%$11.36M$829,941.00-6.5430Upcoming EarningsGap UpEDSAEdesa Biotech2.9635 of 5 stars$3.40+2.1%$21.00+517.6%-27.4%$11.04MN/A0.0020Gap Up Related Companies and Tools Related Companies Biora Therapeutics Alternatives Indaptus Therapeutics Alternatives IN8bio Alternatives ANEW Medical Alternatives Calidi Biotherapeutics Alternatives CERo Therapeutics Alternatives Aytu BioPharma Alternatives Kiora Pharmaceuticals Alternatives Addex Therapeutics Alternatives Edesa Biotech Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MYNZ) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | SponsoredHow high could Bitcoin go?Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mainz Biomed Please log in to your account or sign up in order to add this asset to your watchlist. Share Mainz Biomed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MYNZ Stock Alerts